We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Laboratory Medicine and Nosocomial Infections: Fending Ebolavirus

By LabMedica International staff writers
Posted on 23 Feb 2010
Print article
The organism that was the most alarming to the public was the Ebolavirus. In the early stages, Ebola might not be highly contagious i.e., contact with someone who is in the early stage might not even transmit the disease.

As the illness progresses, bodily fluids from diarrhea, vomiting, and bleeding represent a hazard. Large-scale epidemics occur mostly in poor, isolated areas without modern hospitals or well-educated medical staff. Many areas where the infectious reservoir exists have just these characteristics. In such environments, all that can be done is to immediately cease all needle-sharing or use without adequate sterilization procedures, isolate patients, and observe strict barrier nursing procedures with the use of a medical rated disposable face mask, gloves, goggles, and a gown at all times. This should be strictly enforced for all medical personnel and visitors.

In 2006 a study testing a fast acting, single shot vaccine began. The study was completed in 2008.

In March 2009, a German research scientist in advertently pricked herself with material containing Ebolavirus. It was decided to vaccinate her with the new vaccine, after which she developed a fever Scientific American reported, "At that moment, when she developed the fever, it wasn't clear if it was due to the Ebolavirus," But after the virus' three-week incubation period passed and no other Ebola symptoms surfaced, it appeared that the vaccine—and not the Ebolavirus—was responsible.

Other hemorrhagic viruses, particularly Lassa virus, Nairovirus (causes Crimean-Congo hemorrhagic fever--CCHF), and Marburgvirus cause nosocomial diseases. The findings of laboratory investigation vary somewhat between the viruses-usually the total white cell count decreases, serum liver enzymes increase, and both prothrombin and active partial prothrombin times rise. The hematocrit may be elevated. The serum urea and creatine may be raised but this is dependent on the hydration status of the patient. The bleeding time tends to be prolonged.

New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.